Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs has developed extensive ErbB2 CAR-related products to facilitate CAR-T development. Please feel free to inquire about the specific product you are interested in.
ErbB2, also known as HER2, is a member of the membrane tyrosine kinase (TK) receptors family. The ErbB family is involved in a variety of signaling pathways, regulating biological processes such as proliferation, differentiation, apoptosis, and angiogenesis. It is well known that ErbB2 is an established therapeutic target for breast cancer, and several drugs have been approved to treat ErbB2-positive breast cancer. In addition, ErbB2 is also overexpressed in other solid tumor subpopulations, including cancer types such as colorectal cancer, non-small cell lung cancer, and bladder cancer, etc. ErbB2 targeting therapy is an important solution for solid tumor therapy.
Fig.1 Schematic Diagram of HER2 CAR-T structure and action in cancer.1
We supply extensive CAR expression detection reagents and sensitive testing assays for anti-ErbB2 CART cell expression validation.
Fig.2 HER2-targeted CAR expression test of anti-HER2 CART cells by flow cytometry.2
ErbB2 CAR-T Cytokine Release Test
To assess the releasing level of cytokines during the CART cell interaction with tumor cells, Creative Biolabs provides several suitable assays for different antigen-specific CART projects, including but not limited to ELISA, ELISPOT, cytometric bead array (CBA), intracellular cytokine detection by FACS.
Fig.3 Cytokine secretion detection of anti-HER2 CART cells co-cultured with synovial sarcoma target cells assessed by CBA.2
ErbB2 CAR-T In Vitro Cytotoxicity Assay
To assess the cytotoxicity activity of CART cells, we supply a variety of robust in vitro anti-tumor assays to test the efficacy of CART cells co-cultured with tumor cells, such as luciferase assay, lactate dehydrogenase (LDH) assay, real-time cell analysis assay (RTCA).
Fig.4 In vitro cytotoxicity evaluation of anti-HER2 CAR T cells against synovial sarcoma target cells at indicated E: T ratio. (A) Visualization representation of synovial sarcoma cell line SYO-1 co-cultured with anti-HER2 CAR T cells at 4:1 E:T ratio. (B) In vitro cytotoxicity analysis of anti-HER2 CAR T cells against 3 different synovial sarcoma cells at indicated E: T ratio.2
Phenotype Analysis for ErbB2 CAR-T
We provide a complete list of CART cell phenotype analyses including but not limited to T cell stimulation marker detection, tumor cell apoptosis marker test, T cell exhaustion marker analysis, etc.
Fig.5 Apoptosis analysis of DLD-1 tumor cells co-cultured with HER2-CART cells at 10:1 E:T ratio.1
For in vivo efficacy tests of CART cells, Creative Biolabs specializes in providing a full range of animal models and suitable testing services for efficacy and toxicity evaluation.
CDX Model for ErbB2-CART Efficacy Test
Fig.6 Schematic of the DLD-1 xenograft models for ErbB2-CART.1
Fig.7 In vivo efficacy test of anti-ErbB2 CART in DLD-1-ffLuc xenograft models by IVIS detection.1
PDX Model for ErbB2-CART Efficacy Test
Fig.8 Schematic of the CRC PDX models for ErbB2-CART.1
Fig.9 In vivo efficacy test of anti-ErbB2 CART in CRC PDX models. Left figure shows IVIS detection of CRC PDX models treated with HER2 CAR-T cells. Right figure shows tumor volume measurement of PDX models treated with HER2 CAR-T cells.1
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-ZP8499 | A uniCAR [Anti-CD16A CAR], with a mAb-based CAR Adaptor [Anti-ErbB2 (Herceptin)], a Switchable CAR System | Breast cancer | Lentiviral vector | ||||||
| XS-1122-LX887 | Anti-ErbB2 (X11X91) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X11X91 | Human | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX888 | Anti-ErbB2 (X11X92) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X11X92 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX889 | Anti-ErbB2 (X11X93) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X11X93 | Human | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0123-ZP170 | Anti-ErbB2 (Trastuzumab) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | Trastuzumab | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP171 | Anti-ErbB2 (Pertuzumab) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | Pertuzumab | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP496 | Anti-ErbB2 (P1142) h(scFv-CD3ε) TRuC, pCDTRC1 | Mouse | P1142 | Rabbit | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP701 | Anti-ErbB2 (FRP5) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | FRP5 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP765 | Anti-ErbB2 (XP5) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | XP5 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP766 | Anti-ErbB2 (chA21) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | chA21 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP767 | Anti-ErbB2 (4D5) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 4D5 | Humanized | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP772 | Anti-ErbB2 (C6.5) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | C6.5 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0323-ZP170 | Anti-ErbB2 (Trastuzumab scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | Trastuzumab | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP171 | Anti-ErbB2 (Pertuzumab scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | Pertuzumab | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP496 | Anti-ErbB2 (P1142 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Mouse | P1142 | Rabbit | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP701 | Anti-ErbB2 (FRP5 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | FRP5 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP765 | Anti-ErbB2 (XP5 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | XP5 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP766 | Anti-ErbB2 (chA21 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | chA21 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP767 | Anti-ErbB2 (4D5 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 4D5 | Humanized | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP772 | Anti-ErbB2 (C6.5 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | C6.5 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0923-LX75 | Anti-hErbB2 (CD28-41BB-CD3ζ) CAR-duplex CTLA4 pCDCAR1 Vector | Human | X9X-44 | scFv-CD28-41BB-CD3ζ-duplex CTLA4 | Lentiviral vector | T cell | CAR-T |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
